The compounds of formula (I) are suitable for producing drugs for use in the prophylaxis and therapy of diseases which are associated with an increased matrix metalloproteinase activity. Examples of such diseases are degenerative articular diseases such as osteoarthroses, spondyloses, chondroporosis after articular trauma or prolonged joint immobilization after meniscus or patella injuries or rupture of a ligament, or a disease of the connective tissue such as collagenoses, periodontal diseases, defective wound healing, or chronic diseases of the locomotor system such as inflammatory, immunologically or metabolically mediated acute or chronic arthritides, arthropathies, myalgias or disorders of the bone metabolism or an ulceration, atherosclerosis or stenosis or an inflammatory disease or a tumor disease, tumor metastatic spread, cachexia, anorexia or septic shock.
